Stammschulte T, Brune K, Brack A, Augenstein H, Arends G, Gundert-Remy U
Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland,
Anaesthesist. 2014 Dec;63(12):958-60. doi: 10.1007/s00101-014-2385-9.
A series of cases of postoperative bleeding were reported to the Drug Commission of the German Medical Association (Arzneimittelkommission der deutschen Ärzteschaft, AkdÄ) within the spontaneous reporting system after the regimen for postoperative pain treatment was changed from diclofenac (150 mg per day) to celecoxib (400 mg per day). All patients underwent elective gynecological surgery and 7 out of 11 patients with postoperative bleeding required revision surgery. Although alternative causes for the hemorrhage incidents could not be excluded, the documented circumstances could have been indicative of a possible causal association. Studies on perioperative pain treatment with celecoxib had previously shown no increased risk of hemorrhage. The tendency to hemorrhage observed in the registered cases could not be pharmacologically explained; however, due to the high dosages of celecoxib and the extensive co-medications used, a relative overdosing due to drug interactions or differences in the metabolism of the affected patients was conceivable. Celecoxib is not approved for the treatment of acute postoperative pain although a number of studies were carried out on the effectiveness and safety in patients undergoing surgery.
在术后疼痛治疗方案从双氯芬酸(每日150毫克)改为塞来昔布(每日400毫克)后,一系列术后出血病例通过自发报告系统上报至德国医学协会药物委员会(Arzneimittelkommission der deutschen Ärzteschaft, AkdÄ)。所有患者均接受了择期妇科手术,11例术后出血患者中有7例需要进行翻修手术。尽管不能排除出血事件的其他原因,但所记录的情况可能表明存在因果关系。此前关于塞来昔布围手术期疼痛治疗的研究未显示出血风险增加。在登记病例中观察到的出血倾向无法从药理学角度解释;然而,由于塞来昔布的高剂量以及所使用的大量合并用药,因药物相互作用或受影响患者代谢差异导致相对用药过量是可以想象的。尽管对手术患者的有效性和安全性进行了多项研究,但塞来昔布未被批准用于治疗急性术后疼痛。